Global
中文
EN
About
Development milestones
Mission&Vision
Founder
Research Achievement
Technology Platforms
Single domain antibody
Five core technology platforms
Pipeline
Business cooperation
Product Out-Licensing
Co-Development
Career development
Our Story
Social Recruitment
News
Company News
Media
Contact Us
Company Address
Online Message
×
Home
中文
EN
About
About Novamab
Technology Platforms
Pipeline
Business cooperation
Market target layout
Strategic Cooperation
Career development
News
Company News
Media
Contact Us
Our Story
Share the latest information
Our Story
News
Company News
Media
2023-09-18
The first and only approved Nanobody drug in China contribute tothe performance growth of three listed companies! What are other potential Nanobody drugs in China?
More
2023-09-18
The first and only approved Nanobody drug in China contribute tothe performance growth of three listed companies! What are other potential Nanobody drugs in China?
More
2022-11-11
Exclusive interview with Dr. Wan Yakun: the fifth anniversary of Novamab, the next goal is Ablynx
More
2022-11-02
Wan Yakun of Novamab: Dream of Zhangjiang Science City, and brave the difficulties of nanoantibody pharmaceutical
More
Our Story
